Saccharomyces boulardii DBVPG 6763

Saccharomyces boulardii DBVPG 6763 is a probiotic yeast strain that produces serine proteases and secretory IgA-stimulating factors to competitively exclude pathogenic bacteria and modulate intestinal immune signaling. Its primary mechanism involves secreting a 54-kDa protease that degrades bacterial toxins and neutralizes Clostridioides difficile toxins A and B at the brush border.

Origin & History

Saccharomyces boulardii DBVPG 6763 is a specific diploid strain of probiotic yeast derived from a commercial supplement by Pure Therapro Rx, originally isolated from tropical fruit peels (lychee and mangosteen). It is cultured, lyophilized, and used as a whole-cell live microorganism with genomic mutations that distinguish it from S. cerevisiae.

Historical & Cultural Context

The research provides no traditional medicine context for S. boulardii DBVPG 6763. Modern probiotic use stems from 20th-century isolation, with no documented historical or cultural applications in traditional medicine systems.

Health Benefits

• Eradicates small intestinal bacterial overgrowth (SIBO) in 80% of cirrhosis patients vs 23.1% placebo (RCT, n=38)
• Reduces mortality in decompensated cirrhosis from 42.9% to 5.3% (p=0.007, RCT)
• Prevents antibiotic-associated diarrhea with 84% efficacy across placebo-controlled trials (meta-analysis, n=5029)
• Shows promise for preventing C. difficile infection in hospitalized patients on antibiotics (prospective study, n=1389)
• Decreases inflammatory markers including LPS and CRP in patients with cirrhosis (RCT evidence)

How It Works

S. boulardii DBVPG 6763 secretes a 54-kDa serine protease that proteolytically cleaves C. difficile toxin A receptor-binding domains, preventing epithelial cell internalization and downstream NF-κB-mediated inflammatory cascades. The strain stimulates luminal secretory IgA production via dendritic cell-mediated IL-10 upregulation, reinforcing mucosal barrier integrity and reducing tight junction protein ZO-1 degradation. Additionally, it competitively inhibits pathogenic bacterial adhesion by occupying mannose-sensitive receptor sites on intestinal epithelial cells, directly suppressing SIBO-associated dysbiosis.

Scientific Research

A randomized controlled trial (n=38) demonstrated 80% SIBO eradication and significantly reduced mortality in cirrhosis patients (PMID: 38337613). Systematic reviews of 27 RCTs (n=5029) confirm S. boulardii's efficacy for various diarrheal conditions, while a large prospective study (n=1389) found DBVPG 6763 specifically effective for C. difficile prevention (PMIDs: 20458757, 2868213).

Clinical Summary

A randomized controlled trial (n=38) demonstrated that S. boulardii DBVPG 6763 eradicated SIBO in 80% of cirrhosis patients versus 23.1% in the placebo group, and a separate RCT found mortality in decompensated cirrhosis dropped from 42.9% to 5.3% (p=0.007), suggesting substantial hepatoprotective effects tied to reduced bacterial translocation. A meta-analysis of placebo-controlled trials reported 84% efficacy in preventing antibiotic-associated diarrhea, consistent with mechanistic data on toxin neutralization and mucosal IgA stimulation. Evidence strength is strongest for GI-related endpoints in cirrhosis and antibiotic-associated diarrhea, with most trials using short durations (2–4 weeks) and moderate sample sizes, warranting larger confirmatory studies. The hepatic mortality data, while statistically significant, derive from a single small RCT and should be interpreted cautiously until replicated.

Nutritional Profile

Saccharomyces boulardii DBVPG 6763 is a probiotic yeast strain, not a conventional food ingredient, so traditional macronutrient profiling is not applicable in the dietary sense. However, its compositional and bioactive profile includes: Protein content approximately 40-50% dry cell weight, primarily structural and enzymatic proteins including secreted proteases and phosphatases. Carbohydrates comprise approximately 30-40% dry cell weight, dominated by cell wall polysaccharides: beta-1,3-glucan and beta-1,6-glucan (~50-60% of cell wall mass) and mannoprotein complexes (~40% of cell wall mass), which serve as key immunomodulatory compounds. Lipids account for approximately 5-10% dry cell weight, including ergosterol (a provitamin D2 precursor, ~5-10 mg/g dry weight) and sphingolipids. Bioactive compounds produced or secreted by this strain include: secretory IgA-stimulating mannoproteins, a 54 kDa aspartyl protease that cleaves C. difficile toxins A and B, a 63 kDa phosphatase that dephosphorylates LPS (reducing inflammatory signaling), polyamines (spermidine, spermine) at trace concentrations supporting epithelial repair, and short-chain fatty acid precursors. The strain produces B-vitamins including folate and riboflavin in small quantities during fermentation. Bioavailability note: As a live yeast, it transits the GI tract without systemic absorption under normal conditions; its benefits derive from luminal and mucosal interactions rather than nutritional absorption. Standard therapeutic dose is 250-500 mg/day (approximately 5×10^9 CFU/g dry weight for this strain).

Preparation & Dosage

Clinical studies use 5×10^9 CFU twice daily (Sacchaflor formulation) for C. difficile prevention, or 250 mg (5-10×10^9 CFU) twice daily for 10 days alongside H. pylori therapy. Standard form is lyophilized powder in capsules. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Prebiotics (FOS/GOS), Lactobacillus strains, Zinc carnosine, L-glutamine, Digestive enzymes

Safety & Interactions

S. boulardii DBVPG 6763 is generally well-tolerated; the most commonly reported side effects are mild bloating and flatulence, which are transient and dose-dependent. Because it is a live yeast organism, it is contraindicated in immunocompromised individuals, patients with central venous catheters, and those with confirmed fungemia risk, as rare cases of Saccharomyces fungemia have been documented in critically ill populations. Concurrent use with antifungal agents (e.g., fluconazole, itraconazole) will abolish probiotic viability and negate therapeutic effect, so co-administration should be avoided. Pregnancy and lactation safety data are limited; while no teratogenicity has been observed in animal models, clinical use in pregnant women should be restricted to cases where benefit clearly outweighs risk under physician supervision.